Yeah I'm just assuming that their most recent update, and those going forward, are for the treatment naive cohort. Reasonable given the response in the second line.
I haven't heard the company specifically say but with the way some have gone from SD to a response may be possible for some that do not get SD (and go off therapy) might in time have had a response if treated longer (or treated at a higher dose).
I'd think this is not it. If they did not get SD, then presumably they progressed and could not be labeled as PR later on.
Either way, I think it's relatively clear now.
One thing these PD-1 combo companies don't yet provide is a breakdown of the actual PD-L1 results. In melanoma at least there is some evidence that response to PD-1 monotherapy trends up above 1% PD-L1. I'm mindful that some of these high response rates presented by various combos may have a skewed population of rather high PD-L1 expressing patients.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.